2cureX 관리

관리 기준 확인 2/4

2cureX CEO는 Ole Thastrup, Jan2006 에 임명되었습니다 의 임기는 18.83 년입니다. 총 연간 보상은 SEK 300.00K, 50% 로 구성됩니다. 50% 급여 및 50% 보너스(회사 주식 및 옵션 포함). 는 SEK 2.00M 가치에 해당하는 회사 주식의 23.8% 직접 소유합니다. 2.00M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 2 년입니다.

주요 정보

Ole Thastrup

최고 경영자

SEK 300.0k

총 보상

CEO 급여 비율	50.0%
CEO 임기	18.8yrs
CEO 소유권	23.8%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ole Thastrup 의 보수는 2cureX 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-SEK 26m
Mar 31 2024	n/a	n/a	-SEK 30m
Dec 31 2023	SEK 300k	SEK 150k	-SEK 33m
Sep 30 2023	n/a	n/a	-SEK 33m
Jun 30 2023	n/a	n/a	-SEK 31m
Mar 31 2023	n/a	n/a	-SEK 29m
Dec 31 2022	SEK 150k	n/a	-SEK 30m
Sep 30 2022	n/a	n/a	-SEK 29m
Jun 30 2022	n/a	n/a	-SEK 26m
Mar 31 2022	n/a	n/a	-SEK 25m
Dec 31 2021	SEK 150k	n/a	-SEK 19m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 10m
Mar 31 2021	n/a	n/a	-SEK 8m
Dec 31 2020	SEK 2m	SEK 2m	-SEK 7m
Sep 30 2020	n/a	n/a	-SEK 7m
Jun 30 2020	n/a	n/a	-SEK 8m
Mar 31 2020	n/a	n/a	-SEK 8m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 8m
Sep 30 2019	n/a	n/a	-SEK 6m
Jun 30 2019	n/a	n/a	-SEK 6m
Mar 31 2019	n/a	n/a	-SEK 6m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 7m

보상 대 시장: Ole 의 총 보상 ($USD 27.17K ) Swedish 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 236.30K ).

보상과 수익: 회사가 수익성이 없는 동안 Ole 의 보상이 증가했습니다.

CEO

Ole Thastrup (71 yo)

18.8yrs

테뉴어

SEK 300,000

보상

Mr. Ole Thastrup is CEO of 2cureX AB (publ) since June 2024 and serves as it's Vice Chairman of the Board since January 01, 2024 and served as the Chief Scientific Officer since January 2021 until January...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ole Thastrup	Co-Founder	18.8yrs	SEK 300.00k	23.8% SEK 2.0m
Grith Hagel	Co-Founder	no data	데이터 없음	3.87% SEK 325.9k
Kenneth Johansen	Chief Financial Officer	3.8yrs	데이터 없음	0.023% SEK 1.9k
Jacob Thastrup	Chief Technology Officer	less than a year	데이터 없음	0.062% SEK 5.2k
Manuel Fernandez	Director Quality & Regulatory Affairs	no data	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: 2CUREX 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ole Thastrup	Co-Founder	18.8yrs	SEK 300.00k	23.8% SEK 2.0m
Grith Hagel	Co-Founder	less than a year	데이터 없음	3.87% SEK 325.9k
John Marshall	Member of Clinical Advisory Board	3.3yrs	데이터 없음	데이터 없음
Tonni Bülow-Nielsen	Chairman of the Board	less than a year	데이터 없음	데이터 없음
Jesus Garcia-Foncillas	Member of Clinical Advisory Board	3.3yrs	데이터 없음	데이터 없음
Andrew Beggs	Member of Clinical Advisory Board	3yrs	데이터 없음	데이터 없음
Nathaniel Hutley	Director	less than a year	데이터 없음	데이터 없음
Dan Honeywell	Director	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

경험이 풍부한 이사회: 2CUREX 의 이사회는 경험(평균 재직 기간 2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

2cureX 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

2cureX AB (publ) Approves the Election of New Board Members

2cureX AB (publ) Announces CEO Changes

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

2cureX AB (publ), Annual General Meeting, May 23, 2024

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

Recent updates

2cureX AB (publ) Approves the Election of New Board Members

First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023)

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

New 90-day low: kr16.25

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: kr17.30

2cureX launches world's first CE-marked microtumor test service

New 90-day high - kr22.50

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀